Impact of amiodarone on electrophysiologic properties of pulmonary veins in patients with paroxysmal atrial fibrillation

J Cardiovasc Electrophysiol. 2005 Jan;16(1):39-44. doi: 10.1046/j.1540-8167.2005.04418.x.

Abstract

Introduction: Pulmonary veins (PVs) are the predominant location of triggers for atrial fibrillation (AF), but little is known about the electrophysiologic properties of PVs. In addition, the influence of amiodarone on the electrophysiologic properties of PVs has not been elucidated.

Methods and results: Fifty-five patients with symptomatic and drug-resistant AF were divided into two groups: group 1 patients (n=29) without antiarrhythmic drug therapy at the time of electrophysiologic study (EPS), and group 2 patients (n=26) undergoing continuous long-term treatment with amiodarone. EPS including programmed stimulation of both atria and within the PVs was performed in both groups. In group 1, the effective refractory period (ERP) of all PVs (174 +/- 62 msec) was significantly shorter than the ERP of the left atrium ([LA] 254 +/- 30 msec, P=0.0001) and right atrium ([RA] 221 +/- 29 msec, P=0.0001). The same pattern was observed in group 2 (PV: 210 +/- 58 msec; LA: 259 +/- 35 msec, P=0.0001; RA: 246 +/- 37 msec, P=0.0255). The ERP of all stimulated PVs was significantly lower in group 1 (174 +/- 62 msec) than in group 2 (210 +/- 58 msec; P=0.0001). The ERP of the left superior and right superior PVs and RA but not the left inferior PV and LA were significantly increased in patients treated with amiodarone. Decremental conduction properties were observed in all stimulated PVs, and there were no significantly differences between the maximal decrement of both groups.

Conclusion: The distinctive electrophysiologic properties of PVs are emphasized by amiodarone therapy. Long-term amiodarone treatment is responsible for heterogeneous alteration of the PV electrophysiology, which may account for the individual antiarrhythmic responses in a subset of patients with paroxysmal AF.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Amiodarone / administration & dosage*
  • Anti-Arrhythmia Agents / administration & dosage
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / physiopathology*
  • Female
  • Heart Conduction System / drug effects*
  • Heart Conduction System / physiopathology*
  • Heart Rate / drug effects
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Veins / drug effects*
  • Pulmonary Veins / physiopathology*
  • Refractory Period, Electrophysiological / drug effects
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents
  • Amiodarone